AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7570433
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol 5 mg alone (4 times a day)
Trial: 519476
Drug: Praziquantel split
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel split regimen (two doses of 20 mg/kg given four hours apart)
Trial: 27853049
Drug: Monthly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly regimen (MR): 1.5 g iv methylprednisolone monthly for 3 months
Trial: 27853049
Drug: Weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly regimen (WR): 0.5 g iv methylprednisolone weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks
Trial: 23863351
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS (1.5 mA, 15 min, daily for five days a week, for three weeks)
Trial: 19743621
Drug: modified multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified multidrug therapy (mMDT) including rifampicin, clofazimine, and dapsone for 1 year
Trial: 17082663
Drug: Thrice-weekly low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thrice-weekly low-dose rituximab (20 mg/m2)
Trial: 17082663
Drug: Thrice-weekly low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thrice-weekly low-dose rituximab (60 mg/m2)
Trial: 17082663
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose infusion of rituximab (375 mg/m2)
Trial: 11402249
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (CHO) 1.0 g á kg body mass(‐1)
Trial: 9424000
Drug: Sucralfate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (3 g in 15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Trial: 9424000
Drug: Placebo (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Trial: 3030392
Drug: Combined oestrogen-CPA
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oestrogen-CPA therapy
Trial: 31982885
Drug: Levosimendan (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (treatment group)
Trial: 16522992
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg/d
Trial: 16522992
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 8 mg/d (if needed)
Trial: 11217682
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine against tetanus, diphtheria and polio (Td-IPV)
Trial: 11217682
Drug: Separate Td
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate Td and IPV injections
Trial: 9387055
Drug: Antihyperthyroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihyperthyroid therapy
Trial: 8329293
Drug: Moclobemide treatment
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide treatment (200 mg twice daily)
Trial: 3791629
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 mg every 12 hr for one week)
Trial: 27460004
Drug: Mindfulness training
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness training (MYmind protocol) consisting of 8 weekly 1.5-hour sessions
Trial: 27460004
Drug: Short-acting methylphenidate
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting methylphenidate administered individually
Trial: 15920062
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg daily for 8 weeks
Trial: 11459384
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy (NT)
Trial: 11459384
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cognitive and nutritional therapy (CNT)
Trial: 9220308
Drug: Urapidil (60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (60-120 mg/d)
Trial: 3600277
Drug: antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antithyroid drug methimazole + thyroxine
Trial: 3600277
Drug: beta 1‐selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta 1‐selective adrenoceptor blocking agent metoprolol
Trial: 20701025
Drug: Digoxin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (single oral dose)
Trial: 20701025
Drug: Digoxin with
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin with simultaneous administration of methimazole (in 12 patients)
Trial: 20701025
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment (in 12 patients who were re-assessed after becoming euthyroid)
Trial: 18237823
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 1 g b.i.d. for 3 months
Trial: 18237823
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no change in pre-enrollment therapy)
Trial: 12615677
Drug: Simvastatin, Atorvastatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, Atorvastatin, Cerivastatin
Trial: 27590465
Drug: Swedish massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish massage therapy
Trial: 20486905
Drug: Everolimus (Evr)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (Evr) monotherapy after 10 days of cyclosporine (CsA)
Trial: 20486905
Drug: Everolimus (Evr)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (Evr) monotherapy
Trial: 17464918
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthwash (0.2%) administered for 30 seconds before dental manipulation
Trial: 7619663
Drug: Buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30 mg day‐1 for 4 days and 10 mg on day 5)
Trial: 7619663
Drug: Ipsapirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone (15 mg day‐1 for 4 days and 5 mg on day 5)
Trial: 7619663
Drug: Clonidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.15 mg intravenous administration)
Trial: 19593248
Drug: 7-valent conjugate
RxNorm normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent conjugate pneumococcal vaccine (PnCRM7)
Trial: 19593248
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine randomized communities
Trial: 16420549
Drug: Transdermal 17beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐oestradiol (tE2, n = 33)
Trial: 16420549
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized 17beta‐oestradiol (oE2, n = 37)
Trial: 16420549
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized 17beta‐oestradiol combined with gestodene (oE2 + G, n = 33)
Trial: 15327582
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg kg(‐1) oral morphine sulphate
Trial: 15327582
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg kg(‐1) oral oxycodone hydrochloride
Trial: 15327582
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.25 mg kg(‐1) morphine sulphate with 0.25 mg kg(‐1) oxycodone hydrochloride
Trial: 21911726
Drug: TAC (75/50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (75/50/500 mg/m² every 3 weeks)
Trial: 21911726
Drug: AC (60/600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (60/600 mg/m² every 3 weeks) followed by docetaxel at 100 mg/m² every 3 weeks (AC>T)
Trial: 18159093
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg/daily, n=176)
Trial: 18159093
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg/daily)
Trial: 1633064
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg) with intravenous frusemide (20 mg)
Trial: 1633064
Drug: Frusemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (20 mg)
Trial: 25791143
Drug: Telehealth service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth service model (6 sessions over 22 weeks of combined pharmacotherapy and caregiver behavior training)
Trial: 25791143
Drug: Control service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control service delivery model (treatment with PCPs augmented with telepsychiatry consultation)
Trial: 17302515
Drug: Fortified mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified mineral water (1000 mL/day)
Trial: 12588812
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human TSH and laser therapy
Trial: 31967190
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (200ml inert solution)
Trial: 28169879
Drug: Pirarubicin at
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirarubicin at 25 mg/m administered 11 times throughout the treatment
Trial: 28169879
Drug: Standard-risk group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-risk group regimen with reinduction therapy
Trial: 23320402
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB)
Trial: 16500579
Drug: Warfarin (International
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (International Normalized Ratio 2.5-3)
Trial: 8387607
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus cisplatin (75 mg/m2), cyclophosphamide (400 mg/m2), and mitomycin (10 mg/m2) given intravenously at 3-week intervals
Trial: 28870155
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200 mg capsules self-administered vaginally daily until 36 weeks gestation or delivery)
Trial: 23633700
Drug: 20 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 percent benzocaine gel
Trial: 23633700
Drug: 10 percent
RxNorm normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 percent benzocaine gel
Trial: 22010225
Drug: 250 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 µg/kg of vitamin D(3)
Trial: 18971554
Drug: Irbesartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (100 mg tablet per day)
Trial: 8989341
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (1 mg/kg in 2 mL of saline)
Trial: 8989341
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL of saline)
Trial: 8480077
Drug: Theophylline therapy
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline therapy after vitamin B6 supplementation
Trial: 8480077
Drug: Theophylline therapy
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline therapy after placebo
Trial: 3547879
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide (20 mg)
Trial: 31371616
Drug: DS‐Cav1 (stabilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS‐Cav1 (stabilized subunit vaccine candidate)
Trial: 28760535
Drug: 18.8 mg
RxNorm normalized name: pemoline 18.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18.8 mg dose of AMP XR-ODT with 4% ethanol
Trial: 28760535
Drug: 18.8 mg
RxNorm normalized name: pemoline 18.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18.8 mg dose of AMP XR-ODT with 20% ethanol
Trial: 28760535
Drug: 18.8 mg
RxNorm normalized name: pemoline 18.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18.8 mg dose of AMP XR-ODT with 40% ethanol
Trial: 28760535
Drug: 18.8 mg
RxNorm normalized name: pemoline 18.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18.8 mg dose of AMP XR-ODT with deionized water
Trial: 26185766
Drug: Intramuscularly administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscularly administered drotaverine hydrochloride (40 mg)
Trial: 21387350
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of 0.5 mg metolazone
Trial: 21387350
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of 1 mg metolazone
Trial: 21387350
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of 2 mg metolazone
Trial: 21387350
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 1 mg metolazone
Trial: 12002908
Drug: roxithromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (150 mg, twice daily)
Trial: 9054280
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (11 mg for 1 week and then ≤ 22 mg for 3 weeks)
Trial: 7697691
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg plus hydrochlorothiazide 12.5 mg once daily
Trial: 7697691
Drug: Benazepril alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril alone (10 mg once daily)
Trial: 31493013
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water bath plus physical therapy
Trial: 31493013
Drug: Mud application
RxNorm normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud application procedures plus physical therapy
Trial: 31343477
Drug: Smooth saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth saline injection test (S group)
Trial: 19808924
Drug: Intensified insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified insulin therapy, exenatide, and daclizumab
Trial: 16702822
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate (5 mg/day)
Trial: 12890955
Drug: Tramadol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol alone (20 mg loading dose, continuous infusion of 1 mg/ml tramadol at 8 ml/h)
Trial: 12890955
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (20 ml bupivacaine 0.125% loading dose, continuous infusion of 8 ml/h)
Trial: 12890955
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tramadol and bupivacaine (20 mg tramadol loading dose, 20 ml bupivacaine 0.125% loading dose, continuous infusion of 1 mg/ml tramadol in 20 ml bupivacaine 0.125% at 8 ml/h)
Trial: 10655253
Drug: Nadolol (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (40-160 mg/d)
Trial: 10655253
Drug: Nadolol plus
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol plus isosorbide mononitrate (10-20 mg 3 times per day)
Trial: 8737763
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release oxybutynin tablet (10 mg) after a high fat breakfast
Trial: 8737763
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release oxybutynin tablet (10 mg) in fasting subjects
Trial: 1329480
Drug: Lisinopril, enalapril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril, enalapril, captopril, digoxin
Trial: 30264745
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 2.5% gel with a low glycemic load diet
Trial: 30264745
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 2.5% gel with a normal diet
Trial: 25041917
Drug: Drug-eluting balloon
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting balloon (DEB) angioplasty
Trial: 20632453
Drug: Interferon-alpha (IFN‐alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN‐alpha) therapy
Trial: 16398595
Drug: 2400 mg
RxNorm normalized name: pancreatin 2400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg Chinese red yeast rice (CRYR)
Trial: 10607712
Drug: 480 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 microg granulocyte colony-stimulating factor (G-CSF)
Trial: 10607712
Drug: G-CSF in
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF in vitro
Trial: 8609227
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (30 ng/kg per min) for 3 hours (EPI-3)
Trial: 8609227
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (30 ng/kg per min) for 24 hours (EPI-24)
Trial: 8609227
Drug: Control (baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (baseline before epinephrine infusion)
Trial: 1360807
Drug: Mizolastine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine (5, 10, 20, 40 mg p.o.)
Trial: 1360807
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (HBB) (40 mg, s.c.)
Trial: 31035309
Drug: Cannabigerol (CBG)
RxNorm normalized name: cannabigerolate
DrugBank: Cannabigerol (DB14734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabigerol (CBG) 120 mg/kg
Trial: 24408989
Drug: Acute carnosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute carnosine supplementation (20 mg/kg body weight)
Trial: 22293891
Drug: Levulan-PDT and
RxNorm normalized name: Levulan
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levulan-PDT and placebo (Eucerin as vehicle cream)
Trial: 20871168
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone plus birid triple viable
Trial: 20871168
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone
Trial: 15647778
Drug: Lisinopril (n=22)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (n=22)
Trial: 8485789
Drug: Epidural tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural tramadol (100 mg diluted in 10 ml normal saline)
Trial: 2712272
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine 10 mg, 20 minutes prior to electroconvulsive therapy
Trial: 30414841
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) injections into epicardial fat pads